• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    11/14/24 5:46:35 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IPSC alert in real time by email
    SC 13G/A 1 tm2428137d3_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Century Therapeutics, Inc.

     

    (Name of Issuer)

     

    Common stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    15673T100

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

     

     

     

     

    CUSIP No. 15673T100 Page 2 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,389,259 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,389,259 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,389,259 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
       
    (2)Consists of (i) 1,177,550 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 117,809 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,093,900 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 84,715,961 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2024.

     

     

     

     

     

    CUSIP No. 15673T100 Page 3 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,389,259 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,389,259 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,389,259 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

       

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
       
    (2)Consists of (i) 1,177,550 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 117,809 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,093,900 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 84,715,961 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024.

     

     

     

     

      

    CUSIP No. 15673T100 Page 4 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,389,259 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,389,259 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,389,259 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
       
    (2)Consists of (i) 1,177,550 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 117,809 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,093,900 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 84,715,961 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024.

      

     

     

     

     

    CUSIP No. 15673T100 Page 5 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,389,259 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,389,259 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,389,259 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
       
    (2)Consists of (i) 1,177,550 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 117,809 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,093,900 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 84,715,961 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024.

     

     

     

     

     

    CUSIP No. 15673T100 Page 6 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,389,259 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,389,259 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,389,259 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
       
    (2)Consists of (i) 1,177,550 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 117,809 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,093,900 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 84,715,961 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024.

     

     

     

     

     

    CUSIP No. 15673T100 Page 7 of 14

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,389,259 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,389,259 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,389,259 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,177,550 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 117,809 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,093,900 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 84,715,961 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024.

     

     

     

     

     

    CUSIP No. 15673T100 Page 8 of 14

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    5,389,259 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    5,389,259 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,389,259 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,177,550 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 117,809 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,093,900 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 84,715,961 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024.

     

     

     

     

    CUSIP No. 15673T100 Page 9 of 14

     

    Introductory Note:  This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Century Therapeutics, Inc.
     
    Item 1.
      (a)

    Name of Issuer

     

    Century Therapeutics, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    25 N 38th Street, 11th Floor

    Philadelphia, PA 19104

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     
      (b)

    Address of Principal Business Office or, if none, Residence

         
        New York Office: Palo Alto Office:  
             
        7 Bryant Park 3340 Hillview Avenue  
        23rd Floor Palo Alto, CA 94304  
        New York, NY 10018    
     
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.0001 par value

     
      (e)

    CUSIP Number

     

    15673T100

     

     

     

     

    CUSIP No. 15673T100 Page 10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:  
       
      Not applicable

     

    Item 4. Ownership  
         
      (a) Amount beneficially owned as of September 30, 2024:  

     

      Venrock Healthcare Capital Partners III, L.P.    5,389,259 (1)
      VHCP Co-Investment Holdings III, LLC    5,389,259 (1)
      Venrock Healthcare Capital Partners EG, L.P.    5,389,259 (1)
      VHCP Management III, LLC    5,389,259 (1)
      VHCP Management EG, LLC    5,389,259 (1)
      Nimish Shah    5,389,259 (1)
      Bong Koh    5,389,259 (1)

     

      (b) Percent of class as of September 30, 2024:  

     

      Venrock Healthcare Capital Partners III, L.P.    6.4 % (2)
      VHCP Co-Investment Holdings III, LLC    6.4 % (2)
      Venrock Healthcare Capital Partners EG, L.P.    6.4 % (2)
      VHCP Management III, LLC    6.4 % (2)
      VHCP Management EG, LLC    6.4 % (2)
      Nimish Shah    6.4 % (2)
      Bong Koh    6.4 % (2)

     

      (c) Number of shares as to which the person has, as of September 30, 2024:

     

      (i)     Sole power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   0
      VHCP Co-Investment Holdings III, LLC   0
      Venrock Healthcare Capital Partners EG, L.P.   0
      VHCP Management III, LLC   0
      VHCP Management EG, LLC   0
      Nimish Shah   0
      Bong Koh   0

     

     

     

     

    CUSIP No. 15673T100 Page 11 of 14

     

      (ii)      Shared power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.    5,389,259 (1)
      VHCP Co-Investment Holdings III, LLC    5,389,259 (1)
      Venrock Healthcare Capital Partners EG, L.P.    5,389,259 (1)
      VHCP Management III, LLC    5,389,259 (1)
      VHCP Management EG, LLC    5,389,259 (1)
      Nimish Shah    5,389,259 (1)
      Bong Koh    5,389,259 (1)

     

      (iii) Sole power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   0
      VHCP Co-Investment Holdings III, LLC   0
      Venrock Healthcare Capital Partners EG, L.P.   0
      VHCP Management III, LLC   0
      VHCP Management EG, LLC   0
      Nimish Shah   0
      Bong Koh   0

     

      (iv)      Shared power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.    5,389,259 (1)
      VHCP Co-Investment Holdings III, LLC    5,389,259 (1)
      Venrock Healthcare Capital Partners EG, L.P.    5,389,259 (1)
      VHCP Management III, LLC    5,389,259 (1)
      VHCP Management EG, LLC    5,389,259 (1)
      Nimish Shah    5,389,259 (1)
      Bong Koh    5,389,259 (1)

     

      (1) Consists of (i) 1,177,550 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 117,809 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,093,900 shares held by Venrock Healthcare Capital Partners EG, L.P.
         
        VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
         
      (2) This percentage is calculated based upon 84,715,961 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨

     

     

     

     

    CUSIP No. 15673T100 Page 12 of 14

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable
       
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 15673T100 Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

     

     

    CUSIP No. 15673T100 Page 14 of 14

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on March 4, 2024)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed March 4, 2024)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on March 4, 2024)

     

     

     

    Get the next $IPSC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IPSC

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00Buy
    Rodman & Renshaw
    8/28/2023$28.00 → $5.00Overweight → Neutral
    JP Morgan
    12/27/2022$19.00Buy
    Chardan Capital Markets
    10/31/2022$15.00Buy
    Guggenheim
    10/10/2022$28.00Buy
    Canaccord Genuity
    5/23/2022$27.00Buy
    H.C. Wainwright
    5/12/2022Mkt Perform
    William Blair
    11/19/2021$33.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $IPSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Century Therapeutics Inc.

      SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

      11/27/24 6:51:58 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

      SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      11/14/24 5:46:35 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

      SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      11/14/24 4:08:17 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Financials

    Live finance-specific insights

    See more

    $IPSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

      - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest

      5/9/24 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

      – Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due to lack of observed allo-rejection – –   Company to host conference call on Monday, December 11 at 7:30 AM PT/10:30 AM ET to review ASH data including additional clinical results from Dose Level 1

      12/9/23 12:00:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

      PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. In addition to updated preliminary clinical data as of a more re

      12/6/23 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Quimi Daphne bought $7,657 worth of shares (5,000 units at $1.53) (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      9/16/24 4:18:18 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operations Officer Farid Adrienne sold $563 worth of shares (1,024 units at $0.55), decreasing direct ownership by 0.41% to 250,693 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/7/25 4:38:50 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP Finance & Operations Carr Douglas sold $162 worth of shares (295 units at $0.55), decreasing direct ownership by 0.07% to 410,886 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/7/25 4:38:25 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Finanical Officer Conn Morgan was granted 19,500 shares, increasing direct ownership by 32% to 79,648 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      3/12/25 7:31:34 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and Allo-Evasion™ 5.0 technology PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripoten

      5/15/25 4:01:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

      PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows:

      4/28/25 4:30:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

      PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell therapy programs targeting autoimmune diseases and cancer. The event will feature discussion of CNTY-308, a CD19-targeted CAR-iT investigational cell therapy, CNTY-341, a CD19/CD22 dual-targeted CAR-iT investigational cell therapy, and the company's first solid tumor CAR

      4/15/25 4:01:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00

      8/8/24 10:22:51 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics downgraded by JP Morgan with a new price target

      JP Morgan downgraded Century Therapeutics from Overweight to Neutral and set a new price target of $5.00 from $28.00 previously

      8/28/23 7:15:43 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital Markets initiated coverage on Century Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $19.00

      12/27/22 7:45:12 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Leadership Updates

    Live Leadership Updates

    See more

    $IPSC
    SEC Filings

    See more
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

      - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - Six posters to be presented at upcoming AACR Annual Meeting 2024 highlighting Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein en

      3/14/24 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

      - Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023. A proven leader with over 20 years of global experience across the healthcare industry, Dr. Pfeiffenberger most recently served as Chief Operating Officer at Neogene Therapeutics, a who

      11/9/23 7:00:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Century Therapeutics Inc.

      SCHEDULE 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      5/15/25 4:27:17 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Century Therapeutics, Inc. (0001850119) (Filer)

      5/15/25 4:15:54 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Century Therapeutics Inc.

      10-Q - Century Therapeutics, Inc. (0001850119) (Filer)

      5/15/25 4:15:56 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care